Get the Stockscreener App
160.80
0.15%
-0.2211
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $160.80, with a volume of 387.94K.
It is down -0.15% in the last 24 hours and down -1.00% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$161.02
Open:
$161.44
24h Volume:
387.94K
Relative Volume:
0.17
Market Cap:
$38.37B
Revenue:
$222.29B
Net Income/Loss:
$1.56B
P/E Ratio:
25.09
EPS:
6.41
Net Cash Flow:
$2.44B
1W Performance:
-2.12%
1M Performance:
-1.00%
6M Performance:
+26.57%
1Y Performance:
+68.51%
1-Day Range:
$160.20
$161.82
1-Week Range:
$160.11
$164.41
52-Week Range:
$94.29
$168.44
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
160.78 | 39.25B | 222.29B | 1.56B | 2.44B | 6.41 |
|
MCK
Mckesson Corporation
|
710.91 | 90.44B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
294.89 | 57.77B | 310.23B | 1.69B | 3.58B | 8.62 |
|
HSIC
Henry Schein Inc
|
69.15 | 9.24B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.7844 | 514.48M | 2.22M | -5.63M | -1.68M | -0.24 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health Surges to 331st in Daily Rankings with 3.09 Billion in Trading Volume - AInvest
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2025 on August 12 - The Malaysian Reserve
Cardinal Health: Navigating Growth and Dividends in a Challenging Healthcare Landscape - AInvest
Cardinal Health to Announce Fourth-Quarter and Year-End Results - GuruFocus
Cardinal Health Q4 Earnings Coming August 12: Full Year Results and Future Outlook Preview - Stock Titan
Cardinal Health (CAH) Affirms Long-Term Growth Raises Outlook - MSN
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
Cardinal Health's One Voice Initiative: A Strategic Play for Stakeholder Power and Shareholder Returns - AInvest
Cardinal Health (NYSE:CAH) Launches One Voice Initiative Supporting Independent Pharmacy Advocacy - simplywall.st
Cardinal Health Launches One Voice Initiative To Empower Pharmacy Advocacy - Nasdaq
Cardinal Health Launches One Voice Initiative to Support Independent Pharmacy Advocacy - AInvest
Cardinal Health Launches One Voice Initiative for Pharmacy Advocacy - AInvest
Cardinal Health Unveils Major Financial Initiative to Empower Independent Pharmacy Advocacy Nationwide - Stock Titan
Burns Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Perrigo, Kenvue Brands, 3M, Smith+Nephew, Molnlycke, Cardinal Health, Convatec, Haleon, Coloplast, DeRoyal Industries - GlobeNewswire Inc.
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors - sharewise.com
Cardinal Health (NYSE:CAH) Targets Double-Digit EPS Growth Amid IRA Tailwinds and Healthcare Sector Strength - MSN
Cardinal Health survey reveals 25% of health systems use manual supply tracking; hospitals spent US$147B on medical supplies in 2023, up 4.7% from previous year - Industry Intelligence Inc.
Cardinal Health (CAH) Beat the Market in 2025 with Solid Healthcare Momentum - MSN
Cardinal Health ($CAH) Is Paying a $109M Settlement to Investors — Here’s How to Get Your Share - TradingView
Cardinal Health's (NYSE:CAH) investors will be pleased with their splendid 282% return over the last five years - simplywall.st
Cardinal Health (CAH) Surges Ahead: A Buy for Strong Earnings Momentum and Strategic Value - AInvest
Cardinal Health CEO tops pay rankings, AEP most profitable among Central Ohio public companies - The Business Journals
Cardinal Health Boosts Dividend and Gets Strong Analyst Ratings — What $CAH Investors Should Know - TradingView
Cardinal Health Could Beat Q2 Expectations — And Other News for $CAH Investors - TradingView
Cardinal Health Stock Climbs Ahead of Earnings — And Other News for $CAH Investors - TradingView
Cardinal Health (CAH) Laps the Stock Market: Here's Why - Yahoo Finance
Cardinal Health (CAH) is a Great Momentum Stock: Should You Buy? - Nasdaq
JPMorgan Adjusts Price Target on Cardinal Health to $175 From $156 - MarketScreener
Cardinal Health (CAH) Soars 0.73% on Russell 1000 Index Inclusion - AInvest
Ex-Dividend Reminder: Agilent Technologies, Cardinal Health and Realty Income - Nasdaq
5 Must-Read Analyst Questions From Cardinal Health’s Q1 Earnings Call - Yahoo Finance
How Is Cardinal Health’s Stock Performance Compared to Other Health Care Service Stocks? - MSN
Cardinal Health stock hits all-time high at 166.3 USD - Investing.com
Cardinal Health (CAH) at a 52-Week High: Why This Healthcare Giant's Momentum Is Here to Stay - AInvest
Cardinal Health raises FY 2025 EPS guidance to $8.05-$8.15 amid strong pharma growth and acquisitions - MSN
Deutsche Bank Adjusts Cardinal Health Price Target to $163 From $148 - MarketScreener
Deutsche Bank Raises Price Target on Cardinal Health to $163 From $148, Keeps Hold Rating - marketscreener.com
Cardinal Health (NYSE:CAH) Eyes EPS Growth With IRA Momentum S&P 500 - Kalkine Media
Medical Commode Market Key Players Analysis -Medline - openPR.com
Cardinal Health raises FY25 earnings outlook on investor day - MSN
Cardinal Health Raises Pharmaceutical Segment Profit Guidance 12-13% for FY25 - cheddar.com
Jefferies Adjusts Price Target on Cardinal Health to $190 From $170, Maintains Buy Rating - marketscreener.com
12 Best Healthcare Stocks to Buy Now - Insider Monkey
TD Cowen Affirms Buy Rating on Cardinal Health - Yahoo Finance
Cardinal Health (CAH) Sees Increased Price Target to $182 by Argus | CAH Stock News - GuruFocus
Cardinal Health price target raised to $185 from $170 at UBS - Investing.com
Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Cardinal Health Insiders Sell US$18m Of Stock, Possibly Signalling Caution - Yahoo
Cardinal Health (CAH) Sees Price Target Raised by Morgan Stanley - GuruFocus
Cardinal Health (CAH) Price Target Raised by Citigroup Analyst | CAH Stock News - GuruFocus
Cardinal Health Lifts Earnings Outlook, Impressing Wall Street - Finimize
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):